An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
The Latest on: Biomechanics
via Google News
The Latest on: Parkinson’s disease
- Phil Parkinson decodes Will Grigg's body-language as striker struggles for formon November 18, 2019 at 10:00 pm
Phil Parkinson says Will Grigg's body-language is indicative of the striker's frustration at his lack of goals - not of a player who does not want to be at Sunderland. Grigg is a proven goalscorer at ...
- Parkinson’s Disease: New, Potential Target Discoveredon November 18, 2019 at 7:53 pm
A novel mechanism for the development of Parkinson's disease, which could prove to be the starting point for the development of a more targeted therapy has been discovered by an international research ...
- Michael J. Fox Foundation Honors Andrew Singleton, PhD, with Robert A. Pritzker Prize for Leadership in Parkinson's Researchon November 18, 2019 at 4:08 pm
NEW YORK, Nov. 18, 2019 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded the 2019 Robert A. Pritzker Prize for Leadership in Parkinson's Research to Andrew ...
- Stanford's Parkinson is a semifinalist for top tight end awardon November 18, 2019 at 3:06 pm
Stanford junior Colby Parkinson was named one of the eight semifinalists for the John Mackey Award, which honors the nation’s top tight end and is administrated by the Friends of John Mackey.
- Colby Parkinsonon November 18, 2019 at 2:09 pm
Eight of the nation’s top tight ends were officially named semi-finalists for this season’s John Mackey Award on Monday. The award, named after Pro Football Hall of Fame tight end and former Syracuse ...
- Parkinsons Disease Therapeutics Market Expected to Witness Significant Growth in the Forecast Years 2019-2026on November 18, 2019 at 6:13 am
Nov 18, 2019 (Global QYResearch via COMTEX) -- Ameco Research in its report titled, "Parkinsons Disease Therapeutics Market Analysis 2019 – Projections Report 2026," offers comprehensive insights and ...
- Parkinsons Disease Drugs Market Perspective 2019 with Professional Survey & Competitive Dynamics till 2026on November 17, 2019 at 8:02 pm
Nov 18, 2019 (Market Prediction via COMTEX) -- Amecoresearch.com adds "Parkinsons Disease Drugs Market - Trend Analysis by Several Influencing Growth Factors, Adopting Effective Business Strategies ...
- Researchers evaluate potential of FMT, pre- and probiotics to treat Parkinson's patientson November 15, 2019 at 11:24 am
Constipation is a common complaint in patients with Parkinson's disease (PD). Fecal microbiome transplantation (FMT) and pre- and probiotics are potential options for treating constipation and ...
- Fecal transplantation to treat patients with Parkinson's disease: Hope or hype?on November 15, 2019 at 7:03 am
Scientists review the evidence for using fecal transplantation and pre- and probiotics in patients with Parkinson's disease in the Journal of Parkinson's Disease and conclude that more research is ...
- Parkinson’s Disease: Complications You Should Be aware ofon November 13, 2019 at 10:15 pm
Characterized by tremor, slowed movement, impaired posture, rigid muscles, etc, Parkinson’s is a progressive neurological disorder. In the early stages, it doesn’t show any signs. They appear in the ...
via Bing News